hey, Hugh... I'm optimistic that we can overcome the $3.80 resistance without news...maybe not today though.
One of these days the shorts are going to run like rats abandoning a sinking ship. It'll be quite a sight!
Biotech rules 101:
You don't rush to announce bad data. You DELAY bad data. You only announce GREAT data early.
Especially true in Anavex's case. If news were bad, they would have waited until September and used the next 3 month run-up to raise cash by dilution and exercise warrants. Get cash while you can. The fact that they instead are going to give us some data very early in the 3rd quarter is VERY VERY positive...
The current trial evaluated both 2-73 and Anavex Plus. Half of the patients are already on donezepil, so that group will be the Anavex Plus group
You don't rush to tell people initial data before it's expected or necessary unless it's great. Expect it to be dynamite news! Ignore fiscophil. They just included a generic description of the trial.
It is still unknown though if the trial is fully subscribed.
Lol. The Greek president is just playing politics and mind games. That'll be us in about 20 years or so
I expect IDRA shorts to capitulate big-time tomorrow. Of course it will also depend on the overall market.
On another note, this Greek standoff is quite interesting, actually. Greece might even align with Russia if they exit the Euro. Maybe even sell some islands to Russia for cash (for Russian naval bases). Now that would be something.
Yep, that's why the epilepsy data/potential has markedly increased the stakes here.
Great news about 3-71. However, as an investor, it's a tricky situation if in fact the second drug in the pipeline turns out the be the best. (What if the first drug --2-73--disappoints?)
Totally different mechanisms of action. Not doing the same thing at all as AXON. Ours goes after the cause.
Idera (IDRA).. Very early in the process, but it's gonna be the next ISIS. And in 10 years, maybe even another powerhouse like CELG.
KD-- I'm going in with the attitude that I expect nothing special from the enrollment announcement. That way I won't be disappointed. Anything else would be an unexpected surprise!
Additionally, thus far this stock always goes the opposite direction of my other biotech holding. Doing well while the other went down. And now I expect our other holding to have a GREAT run soon (as you know)... Lol
Hey Prospern. I dunno about the update announcement this week. It might just say we've just completed enrollment, and nothing else. Or, God forbid, what if they hint at a delay, saying final results 4th quarter instead?
So it could be a sell-off event and the last great buying opportunity! Could go both ways-- good or bad.
Either way, this stock will go parabolic at some point.
Because retail owns too many shares. They don't want it to take off yet.
Don't know about Russell. Last year we tanked after that lol.
What I can't figure out is why Bakers even entered TTHI. Phase 2 showed no efficacy at all compared to placebo. Maybe helped with agitation a little (then phase 3 failed even that).